Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GLP-1
Biotech
Zealand slides as Boehringer-partnered obesity drug underwhelms
With the readout echoing earlier data that underwhelmed analysts, shares in Boehringer’s partner Zealand Pharma fell 12% in early trading in Denmark.
Nick Paul Taylor
Oct 1, 2026 6:15am
Lilly sets up next-gen obesity war with phase 3 retatrutide data
Sep 30, 2026 3:06am
Novo agrees $2.6B deal for Hengrui's preclinical GLP-1/GIP drug
Sep 29, 2026 3:50am
Roche’s GLP-1/GIP diabetes data fuel best-in-disease hopes
Sep 22, 2026 5:20am
Fierce Pharma
Novo CEO talks embracing change and staying bullish amid rebrand
Sep 17, 2026 8:45am
Novo scraps $285M pact with Ascendis to develop monthly GLP-1
Sep 15, 2026 5:19am
